Revance Therapeutics, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
Director Julian S Gangolli reports the disposal of Revance Therapeutics shares and restricted stock awards following the completion of a merger with Crown Laboratories.
Form 4: Revance Therapeutics President & CEO Foley Disposes of Shares in Merger with Crown Laboratories
Mark J. Foley, President & CEO of Revance Therapeutics, reports the disposition of shares and restricted stock units following the merger agreement with Crown Laboratories.
CFO Tobin Schilke reports the disposal of Revance Therapeutics shares and restricted stock units (RSUs) following the merger agreement with Crown Laboratories.
Form 4: Revance Therapeutics CLO & GC, Dwight Moxie, Reports Beneficial Ownership Changes Following Merger
Dwight Moxie, CLO & GC of Revance Therapeutics, reports changes in beneficial ownership due to the merger with Crown Laboratories, including the tendering of shares and cancellation of restricted stock units and performance-based restricted stock units.
Following the completion of a merger with Crown Laboratories, Revance Therapeutics' CMO David Hollander reports the disposal of common stock and cancellation of restricted stock units.
Erica Jordan, Chief Commercial Officer of Revance Therapeutics, disposes of shares and restricted stock units following the completion of a merger with Crown Laboratories.
Director Olivia C Ware reports the disposal of Revance Therapeutics shares and cancellation of restricted stock awards following the completion of a merger with Crown Laboratories.
Director Carey O'Connor Kolaja reports the disposal of Revance Therapeutics shares following the completion of a merger with Crown Laboratories.
Director Vlad Coric reports the disposal of Revance Therapeutics shares due to the merger with Crown Laboratories, Inc.
Director Jill Beraud disposed of shares in Revance Therapeutics following the completion of a merger with Crown Laboratories.
Director Chris Nolet reports the disposal of Revance Therapeutics shares and restricted stock awards following the completion of a merger with Crown Laboratories.
Form 4: Revance Therapeutics Director Angus C. Russell Disposes of Shares Following Merger Agreement
Director Angus C. Russell reports the disposal of Revance Therapeutics shares following the completion of a merger with Crown Laboratories, Inc.
Revance Therapeutics CEO Mark Foley reports the vesting of performance-based restricted stock units (PSUs) based on the achievement of revenue goals.
Revance Therapeutics CFO Tobin Schilke reports the vesting of performance-based restricted stock units (PSUs) based on the achievement of revenue goals.
Dwight Moxie, CLO & GC of Revance Therapeutics, reports the vesting of performance-based restricted stock units based on achievement of revenue goals.
Revance Therapeutics' CFO, Tobin Schilke, acquired 1,000 shares of common stock through the company's Employee Stock Purchase Plan on December 31, 2024.
Revance Therapeutics CEO Mark Foley acquired 1,000 shares of common stock through the company's Employee Stock Purchase Plan on December 31, 2024.
A Revance Therapeutics executive sold 3,908 shares of common stock to cover tax obligations related to vesting restricted stock units.
Revance Therapeutics CEO Mark Foley acquired 1,000 shares of common stock through the company's Employee Stock Purchase Plan on June 30, 2024.
Form 4: Revance Therapeutics CFO Tobin Schilke Acquires 1,000 Shares Through Employee Stock Purchase Plan
Revance Therapeutics' CFO, Tobin Schilke, acquired 1,000 shares of common stock through the company's Employee Stock Purchase Plan at a price of $2.1845 per share.
Form 4: Revance Therapeutics Director Olivia C. Ware Reports Acquisition of Shares and Stock Options
Director Olivia C. Ware reports acquisition of 15,000 shares of common stock and 23,458 stock options in Revance Therapeutics.
Director Angus C. Russell reports acquisition of stock and option awards from Revance Therapeutics.
Director Chris Nolet of Revance Therapeutics received 15,000 shares of common stock and an option to purchase 23,458 shares on May 1, 2024.
Director Carey O'Connor Kolaja of Revance Therapeutics received a restricted stock award and a stock option grant on May 1, 2024.
Director Julian S. Gangolli reports acquisition of Revance Therapeutics stock and options as part of annual compensation.
Director Vlad Coric reports acquisition of stock and option awards from Revance Therapeutics.
Director Jill Beraud reports acquisition of 15,000 shares of common stock and 23,458 stock options in Revance Therapeutics, Inc.
Erica Jordan, Chief Commercial Officer of Revance Therapeutics, sold shares to cover tax withholding obligations related to vesting restricted stock units.
Dustin Sjuts, President of Revance Therapeutics, reports the withholding and sale of common stock to cover tax obligations related to vesting restricted stock awards and performance-based restricted stock units.
Dwight Moxie, CLO & GC of Revance Therapeutics, reports disposition of shares to cover tax obligations related to vesting restricted stock awards and performance-based restricted stock units.